Italia markets closed

Agios Pharmaceuticals, Inc. (0HB0.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
27,05-0,56 (-2,01%)
Alla chiusura: 04:40PM BST
Schermo intero
Chiusura precedente27,60
Aperto28,30
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno27,05 - 28,30
Intervallo di 52 settimane27,05 - 28,30
Volume157
Media VolumeN/D
Capitalizzazione12,297M
Beta (5 anni mensile)1,26
Rapporto PE (ttm)N/D
EPS (ttm)-6,43
Prossima data utili01 nov 2022 - 07 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

    – In Adults with Non-transfusion-dependent α- or β-Thalassemia, PYRUKYND® Induced ≥1.0 g/dL Hemoglobin Increase from Baseline in 16 of 20 (80%) Patients Between Weeks 4-12 – – PYRUKYND® Safety Profile Consistent with Label for FDA-approved Indication in Pyruvate Kinase Deficiency – – Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependent α- or β-Thalassemia, Respectively – CAMBRIDGE, Mass., Aug. 11, 2022

  • GlobeNewswire

    ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

    Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announce

  • GlobeNewswire

    Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

    CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the grant of inducement equity awards outside of the company’s 2013 Stock Incentive Plan to its newly appointed chief executive officer, Brian Goff. The grants were approved by the board of directors effective as of August 8, 2022 as inducements material to Mr. Goff entering into employm